Form 4: Mineralys Director Sells $1.57M Shares Post-Option Exercise

Mineralys Therapeutics Director Alexander M. Gold sold over $1.57 million in company common stock after exercising stock options under a Rule 10b5-1 plan.

Summary

• Alexander M. Gold, a Director of Mineralys Therapeutics, Inc. (MLYS), reported a series of transactions involving the exercise of stock options and subsequent sale of common stock.
• On November 11, 2025, Gold exercised options to acquire 15,000 shares of common stock at $10.20 per share and immediately sold all 15,000 shares at weighted average prices of $42.4298 and $47.0816, totaling $659,706 in proceeds.
• On November 12, 2025, Gold exercised options for 6,933 shares at $10.20 per share and sold all 6,933 shares at weighted average prices of $46.50 and $47.2766, totaling $323,900.08 in proceeds.
• On November 13, 2025, Gold exercised options for 2,742 shares at $10.20 per share and 10,000 shares at $12.69 per share, then sold all 12,742 shares at a price of $46.50 per share, totaling $592,403 in proceeds.
• All transactions were conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following these transactions, Alexander M. Gold holds 17,900 stock options exercisable at $10.20, 10,967 stock options exercisable at $10.20, 8,225 stock options exercisable at $10.20, and 34,000 stock options exercisable at $12.69.

Sentiment

Score: 7

Explanation: The sentiment is positive for the insider due to significant profits realized from option exercises and sales. For the company, it's neutral to slightly negative as a large insider sale, even if pre-planned, can sometimes be viewed with caution by the market, though the 10b5-1 plan mitigates this.

Positives

• The reporting person, Alexander M. Gold, realized significant gross profits totaling approximately $1,197,424.08 from exercising stock options at lower prices and selling the shares at substantially higher market prices.
• The transactions were executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to immediate company news, which can mitigate negative market interpretations of insider selling.

Negatives

• The sale of a significant number of shares by a director, even under a pre-arranged plan, could be perceived by some investors as a reduction in insider confidence, although the context of option exercise for liquidity is important.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing details routine insider equity transactions, specifically the exercise of stock options and subsequent sale of shares by a director. Such transactions are common across all industries as executives and directors monetize their equity compensation, often for personal financial planning or diversification, especially when executed under a Rule 10b5-1 plan.

Corporate Governance

Related Party Transactions

• The reported transactions are related party transactions, as they involve a director of Mineralys Therapeutics, Inc. trading in the company's securities.

Stakeholder Impact

• Shareholders: May observe a director's significant sale of shares, which could lead to questions about insider confidence, though the 10b5-1 plan context suggests a planned liquidity event rather than a reaction to new information.
• Employees: No direct impact mentioned, but general market perception of insider activity can indirectly affect employee morale or perception of company value.

Key Dates

Recommendation

The filing details a director's exercise of stock options and subsequent sale of shares, generating substantial personal profit. These transactions were conducted under a pre-arranged Rule 10b5-1 plan, which suggests they are not indicative of a sudden change in sentiment regarding the company's future prospects. While a large insider sale could be viewed negatively, the context of option exercise for liquidity or portfolio diversification makes a 'hold' recommendation appropriate, pending further company-specific or market-wide developments.

Keywords

Mineralys Therapeutics, MLYS, Form 4, Insider Trading, Stock Options, Director, Alexander M. Gold, Equity Transaction, 10b5-1 Plan, Stock Sale